05 July 2018
The global ophthalmic drugs market continues to grow rapidly with expected grow for 2018 at a CAGR of 4.4% in the first half of the forecast period. This is the findings of a new Ophthalmic report just published from Visiongain.
The market is estimated at $24bn in 2017, dominated by the retinal disorder drugs segment.
Key submarkets remain:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
With the key drugs, seeing the greatest revenues up to the end of the forecast period (2028) - This report analysis key drugs such as:
• Lumigan and Ganfort
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
There is an increasing focus to identify diseases that currently do not have a vaccine.
20 June 2019
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.